Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBM-006
- Development stage
- Preclinical
- Lead developer
- Ribomic
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Ophthalmic
01
Overview
RBM-006 is an aptamer therapeutic developed by Ribomic Inc. that specifically binds to and inhibits autotaxin (also known as ENPP2), an enzyme responsible for the synthesis of the lipid mediator lysophosphatidic acid (LPA). By blocking the autotaxin-LPA signaling pathway, RBM-006 aims to prevent tissue fibrosis, which is a key driver in several ocular pathologies. The drug is primarily being developed for proliferative vitreoretinopathy (PVR), where it has shown the ability to inhibit retinal pigment epithelial (RPE) cell proliferation and migration, thereby preventing tractional retinal detachment in animal models. Additionally, its anti-fibrotic mechanism suggests potential therapeutic utility in other retinal conditions such as glaucoma and diabetic retinopathy.
02
Targets
ENPP2 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 2)
Beyond the preview
Go deeper on RBM-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBM-006.